The overall purpose of Core A is to provide a central structure to support the conduct of each of the three highly interrelated projects comprising this program project grant and also to Cores B and C. Core A supports administrative, regulatory, data management and statistical functions for all three projects as well as facilitating interactions with internal and external consultants to assure optimal scientific progress.
Specific Aims of Core A To provide administrative services and infrastructure (meeting scheduling, preparation of progress reports and manuscripts, budgeting, subcontract management, patient care budget development and monitoring, etc.) for Projects 1, 2, and 3 and Cores B and C. To provide regulatory services (protocol and IND preparation, IRB interactions, etc.) for Projects 1, 2 and 3 and Cores B and C. To provide centralized data management support for all protocols in Projects 1, 2, and 3. To provide biostatistical support for all protocols in Projects 1, 2, and 3. To provide internal and external advisory board consultation to assess the progress and direction of Projects 1, 2, and 3 and Cores B and C. To coordinate centralized Flow Cytometry and Molecular Diagnostic Testing for Biomarkers for Projects 1, 2, and 3. Core A provides equal levels of support to Projects 1, 2, and 3 (and also supplies administrative support to Cores B and C).
The overall objective of this Program Project Grant is to improve the outcome of patients with hematologic malignancies by developing curative strategies using radiolabeled monoclonal antibodies in the setting of hematopoietic cell transplantation. This global Specific Aim will be pursued in three interactive, complementary projects that require a smoothly functioning administrative infrastructure.
|Cowan, Andrew J; Stevenson, Phillip A; Gooley, Ted A et al. (2017) Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. Br J Haematol 176:583-590|
|O'Steen, Shyril; Green, Damian J; Gopal, Ajay K et al. (2017) Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res 77:3885-3893|
|Green, Damian J; Press, Oliver W (2017) Whither Radioimmunotherapy: To Be or Not To Be? Cancer Res 77:2191-2196|
|Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19|
|Graf, Solomon A; Gopal, Ajay K (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17:265-74|
|Cowan, Andrew J; Stevenson, Philip A; Cassaday, Ryan D et al. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant 22:380-385|
|Orozco, Johnnie J; Kenoyer, Aimee; Balkin, Ethan R et al. (2016) Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood 127:352-9|
|Chen, Robert; Gopal, Ajay K; Smith, Scott E et al. (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128:1562-6|
|Shadman, Mazyar; Gopal, Ajay K; Kammerer, Britt et al. (2016) Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. Leuk Lymphoma 57:572-6|
|Green, D J; Bensinger, W I; Holmberg, L A et al. (2016) Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 51:1330-1336|
Showing the most recent 10 out of 130 publications